Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 21 March 2003:
Vol. 299. no. 5614, pp. 1830 - 1831
DOI: 10.1126/science.299.5614.1830
Prev | Table of Contents | Next

News Focus

BIOTECHNOLOGY:
Stem Cells Lose Market Luster

Gretchen Vogel

The stock market slump and subsequent evaporation of venture capital is being felt keenly across the biotech landscape. Hit particularly hard is one of the hottest areas of all: human embryonic stem cells and therapeutic cloning, the creation of stem cell lines that are identical genetically to a prospective patient's. The depth of suffering among stem cell companies reflects how far off profits may lie.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)